Skip to main content
. Author manuscript; available in PMC: 2020 Mar 5.
Published in final edited form as: Anal Chem. 2019 Feb 20;91(5):3209–3214. doi: 10.1021/acs.analchem.9b00289

Figure 5.

Figure 5.

Imatinib inhibits the activity of CHK1. (a) Representative MRM and PRM traces for the quantifications of CHK1. (b) Western blot for the validation of the protein expression and activity of CHK1 in K-562 cells with and without imatinib treatment. (c) Clonogenic survival assay results showing the effect of imatinib on sensitizing MDA-MB-231 cells toward NCS. Error bars represent standard deviation. *, 0.01 < p < 0.05; **, 0.001 < p < 0.01; #, no significant difference. The p-values were calculated against the control using the two-tailed, unpaired Student’s t-test.